BACKGROUND: To gain further insight into the natural history of papillary renal cell carcinoma (pRCC), the authors evaluated oncologic impact of important clinical and pathologic prognostic factors and performed survival analyses in a large group of contemporary patients surgically treated for pRCC. METHODS: The institutional nephrectomy database was searched for patients who were managed with radical or partial nephrectomy for pRCC or clear cell RCC (cRCC) from 1994 to 2006. RESULTS: A total of 2157 patients with pRCC (n=245) or cRCC (n=1912) met protocol inclusion criteria. Kaplan-Meier analyses revealed equivalent 5-year cancer-specific survival (CSS) in the nonmetastatic pRCC patient group and revealed significantly decreased CSS in pRCC patients with distant metastases compared with matched cRCC patient cohorts. Presence of venous tumor thrombus was associated with a significant decrease in CSS and was an independent prognostic feature in pRCC patient cohort but not in patients with cRCC (5-year CSS pRCC=35%; cRCC=66%; P= .012). Patients with pRCC were at a significantly increased risk of harboring metastatic lymph nodes compared with patients with cRCC (13% and 8.6%, respectively; P= .019); however, presence of lymph node metastases in patients with pRCC was associated with a relatively indolent disease course (5-year CSS pRCC=65%; cRCC=19%; P= .029). CONCLUSIONS: The authors demonstrated significant differences in presentation, prognostic features, and patient outcomes among papillary and clear cell histologic subtypes of RCC. The authors' findings may potentially link unique molecular genetics that have been reported in pRCCs to its distinct clinical behavior.
BACKGROUND: To gain further insight into the natural history of papillary renal cell carcinoma (pRCC), the authors evaluated oncologic impact of important clinical and pathologic prognostic factors and performed survival analyses in a large group of contemporary patients surgically treated for pRCC. METHODS: The institutional nephrectomy database was searched for patients who were managed with radical or partial nephrectomy for pRCC or clear cell RCC (cRCC) from 1994 to 2006. RESULTS: A total of 2157 patients with pRCC (n=245) or cRCC (n=1912) met protocol inclusion criteria. Kaplan-Meier analyses revealed equivalent 5-year cancer-specific survival (CSS) in the nonmetastatic pRCCpatient group and revealed significantly decreased CSS in pRCCpatients with distant metastases compared with matched cRCC patient cohorts. Presence of venous tumor thrombus was associated with a significant decrease in CSS and was an independent prognostic feature in pRCCpatient cohort but not in patients with cRCC (5-year CSSpRCC=35%; cRCC=66%; P= .012). Patients with pRCC were at a significantly increased risk of harboring metastatic lymph nodes compared with patients with cRCC (13% and 8.6%, respectively; P= .019); however, presence of lymph node metastases in patients with pRCC was associated with a relatively indolent disease course (5-year CSSpRCC=65%; cRCC=19%; P= .029). CONCLUSIONS: The authors demonstrated significant differences in presentation, prognostic features, and patient outcomes among papillary and clear cell histologic subtypes of RCC. The authors' findings may potentially link unique molecular genetics that have been reported in pRCCs to its distinct clinical behavior.
Authors: Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino Journal: Curr Urol Rep Date: 2014-05 Impact factor: 3.092
Authors: Massimo Galia; Domenico Albano; Alberto Bruno; Antonino Agrusa; Giorgio Romano; Giuseppe Di Buono; Francesco Agnello; Giuseppe Salvaggio; Ludovico La Grutta; Massimo Midiri; Roberto Lagalla Journal: Br J Radiol Date: 2017-07-13 Impact factor: 3.039
Authors: Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh Journal: Nat Rev Nephrol Date: 2014-01-14 Impact factor: 28.314
Authors: Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa Journal: Eur Radiol Date: 2012-08-21 Impact factor: 5.315
Authors: Sandra Steffens; Frederik C Roos; Martin Janssen; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Kerstin Junker; Markus A Kuczyk; Andres J Schrader Journal: Virchows Arch Date: 2014-09-02 Impact factor: 4.064
Authors: Janice P Dutcher; Paul de Souza; David McDermott; Robert A Figlin; Anna Berkenblit; Alexandra Thiele; Mizue Krygowski; Andrew Strahs; Jay Feingold; Gary Hudes Journal: Med Oncol Date: 2009-02-20 Impact factor: 3.064